Modified lysine-mimetic compounds

摘要

The disclosure relate to lysine mimetic compounds of formula (III) having pharmacological activity, such as antiarrhythmic activity, and desirable bioavailability properties, wherein the variables shown in the structure of foemula (III) are as defined in the specification. The present teachings further relate to pharmaceutical compositions comprising such compounds and methods of using and making such compounds and compositions for the prevention or treatment of a pathological condition selected from cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions; Type I or Type II diabetes; diabetic retinopathy; diabetic neuropathy; atherosclerosis; CNS related conditions; seizures; ischemia; dental tissue disorders; kidney diseases; anaemia; leukopenia; thrombocytopenia; pancytopenia; superficial wounds; deep wounds resulting from trauma; bone fractures; erectile dysfunction; urinary bladder incontinence; neuropathic pain; subchronic and chronic inflammation; cancer; failure of bone marrow; stem cell transplantation; conditions arising during transplantation of cells and tissues; conditions arising during medical procedures; conditions caused by an excess of reactive oxygen species, free radicals or nitric oxide; diseases or disorders of pregnancy; female infertility or stroke.